Cytarabine dose for acute myeloid leukemia [6]

New England Journal of Medicine

Volumn 364, Issue 22, 2011, Pages 2167-2168

  Medeiros, Bruno C ^a   Othus, Megan ^b   Appelbaum, Frederick R ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; ANTINEOPLASTIC ANTIMETABOLITE; CD135 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER SURVIVAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; EVENT FREE SURVIVAL; HIGH RISK PATIENT; HUMAN; KARYOTYPE; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT RESPONSE; DRUG ADMINISTRATION; DUPLICATE GENE; GENETICS; NOTE; REMISSION; AGED; MIDDLE AGED; MONOSOMY; MORTALITY; REGRESSION ANALYSIS; SURVIVAL; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; FMS-LIKE TYROSINE KINASE 3; GENES, DUPLICATE; HUMANS; LEUKEMIA, MYELOID, ACUTE; REMISSION INDUCTION; AGED; MIDDLE AGED; MONOSOMY; REGRESSION ANALYSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79957798415     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (1)

1. Medeiros BC, Othus M, Fang M, Roulston D, Appelbaum FR. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood 2010;116:2224-8.